New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Friday, Nov 20, 2026
Export ABBV’s income statement to Excel — free account
AbbVie Inc.
ABBVHealthcare Drug Manufacturers General
AbbVie Inc.’s revenue for fiscal 2025 (year ended December 2025) was $61.2 billion, up 8.57% from fiscal 2024.
- Revenue
- +10.3%
- EPS
- +2,270.0%
- Free cash flow
- +9.97%
- Total debt
- +17.7%
Quarter to September 2026, against a year earlier
288.61
5.10
+1.80%
Follow ABBV
Alert me
Revenue to profit Twelve months to Sep 30, 2026
Of every $100 of revenue, $15.68 was left as profit. Gross margin has risen three quarters running, from 70.2% to 73.7%. What is an income statement?
| Revenue | 66.0 | 100.0% |
|---|---|---|
| Cost of revenue | −17.3 | −26.3% |
| Gross profit | 48.7 | 73.7% |
| Research & development | −10.0 | −15.1% |
| Selling, general & admin | −15.2 | −23.0% |
| Other operating costs | −2.3 | −3.5% |
| Operating income | 21.2 | 32.2% |
| Other income, net | −8.4 | −12.8% |
| Income tax | −2.5 | −3.7% |
| Net income | 10.3 | 15.7% |
Net margin (right axis)
| Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|
| Revenue | $61.2B | $62.8B | $64.4B | $66.0B |
| Operating income | $15.1B | $15.3B | $16.9B | $21.2B |
| Net income | $4.2B | $3.6B | $6.3B | $10.3B |
| Net margin (right axis) | 6.9% | 5.8% | 9.8% | 15.7% |
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Revenue |
66,014.00 | 64,386.00 | 62,819.00 | 61,160.00 |
+8 more TTM periods Free account |
Cost of Revenue |
17,346.00 | 18,365.00 | 18,420.00 | 18,204.00 | |
Gross Profit |
48,668.00 | 46,021.00 | 44,399.00 | 42,956.00 | |
R&D Expenses |
9,962.00 | 9,714.00 | 9,501.00 | 9,096.00 | |
SG&A Expenses |
15,192.00 | 14,674.00 | 14,295.00 | 14,010.00 | |
Operating Income |
21,233.00 | 16,870.00 | 15,332.00 | 15,075.00 | |
Non-operating Income/Expense |
(8,419.00) | (8,171.00) | (9,357.00) | (8,478.00) | |
Non-operating Interest Expenses |
2,679.00 | 2,646.00 | 2,645.00 | 2,627.00 | |
| 12,814.00 | 8,699.00 | 5,975.00 | 6,597.00 | ||
Income Tax Provision |
2,466.00 | 2,383.00 | 2,334.00 | 2,364.00 | |
Income after Tax |
10,348.00 | 6,316.00 | 3,641.00 | 4,233.00 | |
Dividends (Preferred) |
— | — | 60.00 | 80.00 | |
Non-Controlling Interest |
6.00 | 6.00 | 6.00 | 7.00 | |
Net Income Common |
10,302.00 | 6,270.00 | 3,595.00 | 4,186.00 | |
EPS (Basic) |
5.81 | 3.54 | 2.03 | 2.36 | |
EPS (Diluted) |
5.81 | 3.54 | 2.03 | 2.36 | |
Shares (Basic, Weighted) |
1,769.25 | 1,769.25 | 1,769.00 | 1,768.50 | |
Shares (Diluted, Weighted) |
1,772.50 | 1,772.50 | 1,772.50 | 1,772.00 | |
Gross Margin |
73.72% | 71.48% | 70.68% | 70.24% | |
EBIT Margin |
32.16% | 26.20% | 24.41% | 24.65% | |
EBT margin |
19.41% | 13.51% | 9.51% | 10.79% | |
Net Profit Margin |
15.61% | 9.74% | 5.72% | 6.84% | |
Free Cash Flow Margin |
28.59% | 28.28% | 31.81% | 29.13% | |
EBITDA |
28,900.00 | 25,586.00 | 24,215.00 | 24,061.00 | |
EBIT |
21,233.00 | 16,870.00 | 15,332.00 | 15,075.00 | |
EPS (Diluted, from Cont. Ops) |
5.84 | 3.56 | 2.05 | 2.39 | |
EPS (Diluted, Consolidated) |
5.84 | 3.56 | 2.05 | 2.39 | |
EPS (Basic, Consolidated) |
5.85 | 3.57 | 2.06 | 2.39 | |
Shares (Diluted, Average) |
1,772.75 | 1,772.75 | 1,772.75 | 1,772.25 | |
EPS (Basic, from Continuous Ops) |
5.85 | 3.57 | 2.06 | 2.39 | |
Income from Continuous Operations |
10,348.00 | 6,316.00 | 3,641.00 | 4,233.00 | |
Consolidated Net Income/Loss |
10,348.00 | 6,316.00 | 3,641.00 | 4,233.00 | |
EBITDA Margin |
43.78% | 39.74% | 38.55% | 39.34% | |
Operating Cash Flow Margin |
30.43% | 30.30% | 33.79% | 31.12% |
In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 18, 2026